Vaccinia Virus Antikörper (Biotin)

Produktnummer ABIN955498

Dieser Kaninchen Polyklonal Antikörper detektiert spezifisch Vaccinia Virus in EIA und IHC (p). Es zeigt Reaktivität gegenüber Proben von Vaccinia Virus (VACV).

Kurzübersicht für Vaccinia Virus Antikörper (Biotin) (ABIN955498)

Target: Vaccinia Virus (VACV) (Vaccina Virus (VACV))

Reaktivität: Vaccinia Virus (VACV)

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Vaccinia Virus Antikörper ist konjugiert mit Biotin

Applikation: Enzyme Immunoassay (EIA), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Produktdetails anti-Vaccinia Virus Antikörper (Biotin)

Aufreinigung: Protein A Chromatography

Immunogen: Lister Strain (mixture of virions and ICPs)

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 4-5 mg/mL (OD280 nm, E0.1% = 1.4)

Buffer: 0.01 M PBS pH 7.2 containing 0.09 % Sodium Azide as preservative. Contains no stabilizing proteins.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: -20 °C

Informationen zur Lagerung: Store the antibody undiluted at -20 °C only.

Details zu Vaccinia Virus

Target: Vaccinia Virus (VACV) (Vaccina Virus (VACV))

Andere Bezeichnung: Vaccinia Virus

Substanzklasse: Virus

Hintergrund: Vaccinia virus is an Orthopoxvirus, containing double stranded DNA. Fusion protein plays an important role in the entry of enveloped virus into cells. As vaccinia virus has a wide host range, it is conceivable that certain cellular components that are ubiquitously expressed on the cell mediate virus infection. The study of the entry process, attachment, fusion and the proteins and receptors involved is complex. During vaccinia virus infection, the fusion process is attributed to the action of the 14KDa protein (A27L). The N terminus of this protein recognises heparan sulfate on the cell surface. It interacts with the negative charges of sulfates of glycosaminoglycans (GAGs). Therefore, antibodies that recognize this 14KDa protein are able to neutralize vaccinia virus infection and enable identification other viral and cellular proteins which participate in the vaccinia virus entry process.